Dear Friends,

As we usher in a new decade, it is the perfect time to reflect on the progress we made in 2019, and to look ahead to 2020 with excitement. I am honored to work alongside the talented Dana-Farber scientists, clinicians, and administrators who come to work every day with unyielding energy and fresh ideas to defeat cancer, giving our patients and their families continued hope.

One such scientist is William G. Kaelin Jr., MD, who received the 2019 Nobel Prize in Medicine jointly with two other scientists, for discoveries of how cells sense and adapt to oxygen availability. These findings have already led to important medical applications, including new cancer therapies, and stem from basic research that is simply not possible without philanthropy. This is an extraordinary honor for all of us at Dana-Farber, and demonstrates that, with your help, we are well-positioned to move the field forward.

Our commitment to excellence and innovation has resulted in many other milestone achievements this year. For example, we made significant strides toward prevention and early detection of cancer with the launch of three first-of-their-kind centers. The Lynch Syndrome Center and the Li-Fraumeni Syndrome and TP53 Center seek to help patients with inherited disorders that greatly increase their risk of many cancers, and the Center for Prevention of Progression focuses on stopping precursor conditions from becoming blood cancers. As you will read in the story about Jennifer Perry, these efforts are having a real and immediate impact on patient lives.

Our bold vision for the road ahead is reflected in the new Dana-Farber and Jimmy Fund branding that you see throughout this letter. The new Dana-Farber logo, dubbed “the Lens,” implies looking through a microscope in which a stylized D and F overlap, signifying the intersection of compassionate care and innovative, world-class cancer research that has been our hallmark since 1947. And our new “Jimmy” maintains his historic spirit while offering a warm welcome to our next generation of supporters.

Science fuels everything we do at Dana-Farber, but the true source of this energy is our people. It is our entire community—our passionate faculty and staff, and you, our generous donors—who make our breakthroughs possible and inspire us to keep pushing boundaries to improve the lives of our patients.

Thank you for all that you do to help us move closer to a world without cancer.

Sincerely,

Laurie H. Glimcher, MD
President and CEO
Richard and Susan Smith Professor of Medicine
Curative Potential for CLL
Dana-Farber introduced a novel combination therapy for chronic lymphocytic leukemia (CLL) that resulted in many patients under 65 achieving undetected minimal residual disease after two years of treatment, suggesting curative potential for a broad patient population.

Early Detection for Ovarian Cancer
Ovarian cancer is notoriously difficult to detect early. But in a recent breakthrough, researchers identified 34 new genes associated with an increased risk for developing earliest-stage ovarian cancer, laying the groundwork for new approaches that could halt cancer before it advances.

Preventing Pancreatic Cancer
Dana-Farber researchers have discovered a rare inherited gene mutation that dramatically raises the lifetime risk of pancreatic and other cancers. This discovery could lead to routine testing of people with a family history of pancreatic cancer to detect the disease at an earlier, more treatable stage.

New Hope for Pediatric Cancer
Effective treatments for renal medullary carcinoma tumors, a rare and deadly pediatric kidney tumor, have eluded doctors for years. But a recent Dana-Farber study offers hope: researchers have discovered a key vulnerability that can be exploited by an existing drug used for treating other cancers in adults.

Immunotherapy for Glioblastoma
For the first time ever, Dana-Farber researchers provoked an immune response against glioblastoma by using a personalized 'neoantigen' vaccine that trains a patient’s own immune cells to attack the tumor. This discovery provides hope to patients fighting a disease that has, until now, evaded immunotherapy.

Reducing Disparities
A Dana-Farber study revealed that black men diagnosed with prostate cancer classified as low risk may in fact have a more aggressive form of the disease that is more likely to be fatal than in non-black men. This finding sets the stage for further research into the possible causes of this disparity.

Making Transplant History
Dana-Farber made history by performing the first outpatient stem cell transplant in New England. Our new ambulatory transplant center is designed to reduce or even eliminate hospital stays for patients receiving reduced-intensity conditioning.

Responding to Patient Needs
In response to the alarming increase in colon and rectal cancer patients under 50, Dana-Farber established the Young-Onset Colorectal Cancer Center, one of the first in the country dedicated to this distinct patient population.

Caring for the ‘App’ Generation
Young adult patients face special challenges—cancer can disrupt education, career, family planning, or parenting of young children. To address the emotional burden of these issues, Dana-Farber developed “iaya,” a smartphone app that provides these patients with coping exercises and a digital space to connect with peers.

Emergency Care
Cancer patients often experience symptoms that require urgent evaluation. To help patients avoid unnecessary trips to the emergency room, Dana-Farber opened the acute Care Clinic, an extension of the Yawkey Center for Cancer Care that provides urgent care from specialists who understand the unique needs of our cancer patients.

Increasing Access to Care
Committed to bringing high quality care to patients closer to where they live, Dana-Farber added Cape Cod Hospital and Maine-based New England Cancer Specialists to the Dana-Farber Cancer Care Collaborative in 2019, and launched a collaboration in Brazil to help develop a network of five comprehensive cancer centers across that country.

To learn more about our world-class research and patient care, or to get involved, please visit:
Dana-Farber.org | JimmyFund.org

Follow us: @Dana-Farber | @TheJimmyFund
Jennifer’s Story

KNOWLEDGE IS POWER

2019 Nobel Prize: Dana-Farber researcher William G. Kaelin Jr., MD, won the 2019 Nobel Prize in Medicine. Kaelin, who is the Sidney Farber, MD, Professor of Medicine, shares the prize with two other scientists for their basic research into how cells sense and adapt to oxygen availability, part of the underlying biology that fuels cancer growth.

Honors RECOGNITION AND RANKINGS

Top in New England, Top 5 Nationwide
Dana-Farber Cancer Institute has been the top ranked cancer hospital in New England by U.S. News and World Report for 19 consecutive years, and is ranked in the top 5 nationally for both adult and pediatric cancer programs.

In Good Company
Dana-Farber Cancer Institute was ranked #7 on the list of Top 100 Women-Led Businesses in Massachusetts, The Boston Globe Magazine and The Commonwealth Institute’s annual list of the most noteworthy companies and nonprofits led by women.

Top Doctors
Boston magazine named more than 115 physicians and surgeons affiliated with Dana-Farber Cancer Institute to its annual “Top Doctors” guide, recognizing their expert and compassionate care.

Nursing Excellence
Dana-Farber was awarded Magnet® status by the American Nurses Credentialing Center for the fourth consecutive time. This prestigious designation recognizes excellence in nursing practice and health care delivery and is awarded to only 8 percent of hospitals in the U.S.

NCI Outstanding Investigators
In 2019, six Dana-Farber researchers were named Outstanding Investigators by the National Cancer Institute. This recognition gives the Institute a total of 15 such awards, the most of any single institution.

Giants of Cancer Care
Stephen Hodi, MD, and Eric Winer, MD, have been named Giants of Cancer Care® by OncLive for their exceptional contributions to cancer research and clinical practice.

Like her mother, Jennifer Perry was diagnosed with breast cancer at age 36. Although she knew that a lot of her family members had been treated for cancer, it wasn’t until several years after her diagnosis that Perry learned she had Li-Fraumeni syndrome (LFS) after a genetic test at Dana-Farber.

LFS is a familial predisposition for cancer thought to affect as many as 1 in 5,500 people. Because of her condition, Perry is at high risk of additional cancers in her lifetime. But Dana-Farber’s newly launched Li-Fraumeni Syndrome and TP53 Center—the first comprehensive, multidisciplinary center in the world that specializes in this unique condition—helps her manage that risk.

Perry’s care team is providing her with a combination of personalized cancer risk management plans and social support. Under that guidance, Perry is learning to cope with LFS and even to thrive as a patient advocate.

“As stressful as it is, I would rather find something early and deal with it,” says Perry. “Knowledge is power.”
Dana-Farber Cancer Institute has been the top ranked cancer hospital in New England by U.S. News and World Report for 19 consecutive years, and is ranked in the top 5 nationally for both adult and pediatric cancer programs.

Cigall Kadoch, PhD, received the 2019 Martin and Rose Wachtel Cancer Research Prize from the American Association for the Advancement of Science for outstanding, early career work in cancer research.

Avinash Das Sahu, PhD, received a 2019 Michelson Prize from the Michelson Medical Research Foundation and the Human Vaccines Project for innovative work using AI to identify drugs that can boost immunotherapy response for patients.

Karen Fasciano, PsyD, received the Outstanding Clinical Care Award from the American Psychosocial Oncology Society, recognizing an exceptional psychosocial oncology clinician for outstanding contributions to the field.